View text source at Wikipedia
| |||
Names | |||
---|---|---|---|
Preferred IUPAC name
(5Z)-7-{(2R,3S,4S,6Ξ)-4,6-Dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-2-yl}hept-5-enoic acid | |||
Identifiers | |||
3D model (JSmol)
|
|||
ChEBI | |||
ECHA InfoCard | 100.165.003 | ||
MeSH | Thromboxane+B2 | ||
PubChem CID
|
|||
UNII | |||
CompTox Dashboard (EPA)
|
|||
| |||
Properties | |||
C20H34O6 | |||
Molar mass | 370.48 g/mol | ||
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Thromboxane B2 (TXB2) is an inactive metabolite/product of thromboxane A2. It is almost completely cleared in the urine.
It itself is not involved in platelet activation and aggregation in case of a wound, but its precursor, thromboxane A2, is. Thromboxane A2 synthesis is the target of the drug aspirin, which inhibits the COX-1 enzyme (the source of thromboxane A2 in platelets). [1]
2-(3,4-Di-hydroxyphenyl)-ethanol (DHPE) is a phenolic component of extra-virgin olive oil. An olive oil fraction containing DHPE can inhibit platelet aggregation and thromboxane B2 formation in vitro.[2]